{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Part+1%29&page=2", "query": { "intervention": "Placebo (Part 1)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Part+1%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T17:47:15.892Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04313400", "title": "Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "1.1% w/w AMTX-100 CF-part1", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "1.1% w/w AMTX-100 CF3-part2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amytrx Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2020-03-10", "completion_date": "2024-01-02", "has_results": true, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 11, "location_summary": "Cerritos, California • Encino, California • Long Beach, California + 8 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "North Hollywood", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04313400" }, { "nct_id": "NCT03513016", "title": "A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteoarthritis, Knee" ], "interventions": [ { "name": "UBX0101", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Unity Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 78, "start_date": "2018-05-16", "completion_date": "2019-04-12", "has_results": false, "last_update_posted_date": "2020-04-20", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 7, "location_summary": "El Cajon, California • La Mesa, California • Miami, Florida + 4 more", "locations": [ { "city": "El Cajon", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03513016" }, { "nct_id": "NCT04586985", "title": "Safety, Tolerability and Pharmacokinetics of FTX-6058", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Subjects", "Sickle Cell Disease" ], "interventions": [ { "name": "FTX-6058/placebo oral capsule(s)", "type": "DRUG" }, { "name": "FTX-6058 - Two Dosing Periods", "type": "DRUG" }, { "name": "FTX-6058 / Midazolam Syrup", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fulcrum Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 109, "start_date": "2020-10-26", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2022-12-12", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Overland Park, Kansas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04586985" }, { "nct_id": "NCT00117676", "title": "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TDF", "type": "DRUG" }, { "name": "ADV", "type": "DRUG" }, { "name": "TDF placebo", "type": "DRUG" }, { "name": "ADV placebo", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 382, "start_date": "2005-02", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 17, "location_summary": "La Jolla, California • Pasadena, California • San Diego, California + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00117676" }, { "nct_id": "NCT01133678", "title": "Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 50, "start_date": "2010-05-04", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2020-05-08", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 2, "location_summary": "Chicago, Illinois • Evanston, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01133678" }, { "nct_id": "NCT03451851", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Guselkumab", "type": "DRUG" }, { "name": "Placebo for guselkumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 120, "start_date": "2018-07-11", "completion_date": "2026-12-18", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 10, "location_summary": "Palo Alto, California • San Diego, California • Macon, Georgia + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Macon", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rolling Meadows", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03451851" }, { "nct_id": "NCT07809919", "title": "A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Visceral Leishmaniasis", "Chagas Disease" ], "interventions": [ { "name": "LXE408", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iohexol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 88, "start_date": "2018-12-21", "completion_date": "2021-09-27", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07809919" }, { "nct_id": "NCT01727336", "title": "Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Renal Cell Carcinoma" ], "interventions": [ { "name": "Dalantercept and axitinib", "type": "DRUG" }, { "name": "Placebo and axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2012-12", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 36, "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Irvine, California + 32 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01727336" }, { "nct_id": "NCT01517945", "title": "Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Rare Cancer" ], "interventions": [ { "name": "AIM materials and assessments", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2012-01", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01517945" }, { "nct_id": "NCT02906020", "title": "A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "venglustat GZ/SAR402671", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 273, "start_date": "2016-12-15", "completion_date": "2021-05-27", "has_results": true, "last_update_posted_date": "2022-05-24", "last_synced_at": "2026-09-29T17:47:15.892Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02906020" } ] }